symbol ATAI
会社名 ATA Inc. (ATA)
分野(sector) Consumer Services   消費者サービス
産業(industry) Other Consumer Services  
業種 事業サポ―トサ―ビス   サ―ビス(Services)
概要 事業概要 エー・ティー・エー(ATA Inc.)は中国においてコンピューターベースのテスト・サービスを提供する。同社は中国においてテスト・デリバリー・プラットフォーム、テスト技術及びテスト提供業務を利用してコンピューターベースのテストの作成・配信向けにサービスを提供する。同社のコンピューターベースのテスト・サービスは情報技術(IT)サービス、銀行業務、証券、教育及び保険を含む多数の業界のプロ免許下付と認定試験に使用される。コンピューターベースのテスト・サービスの顧客は主として専門家団体、中国政府機関及び国営企業を含む。同社のテストセンターネットワークには、中国全土に約3035のテストセンターがある。そのネットワークにより、クライアントはコンピューターベースおよびペーパーベースのテストを管理できる。同社はビジネス開発目的で約1180万件の無料テストを含む約8810万件のテストを実施する。   ATAはケイマン諸島籍の持株会社。子会社を通して、コンピュ―タベ―スの試験サ―ビス、試験ベ―スの教育プログラム、試験準備とトレ―ニング・ソリュ―ション及び関連サ―ビスを中国で提供。コンピュ―タベ―スの試験サ―ビスは、ITサ―ビス、銀行、証券、教育保険などの様々な業界で、プロの免許や認定試験のために使用される。本社は中国北京市。   atai is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. atai was founded in 2018 as a response to the significant unmet need and lack of innovation in the mental health treatment landscape. atai is dedicated to acquiring, incubating and efficiently developing innovative therapeutics to treat depression, anxiety, addiction, and other mental health disorders. atai's business model combines funding, technology, scientific and regulatory expertise with a focus on psychedelic therapy and other drugs with differentiated safety profiles and therapeutic potential. By pooling resources and best practices, atai aims to responsibly accelerate the development of new medicines across its companies, seeking to effectively treat and ultimately heal mental health disorders. atai's mission is to bridge the gap between what the mental healthcare system currently provides and what patients need. atai is headquartered in Berlin, with offices in New York and London.
本社所在地 1/F East Gate Building No. 2 Jian Wai Soho No. 39 Dong San Huan Zhong Road Beijing Chao Yang District 100022 CHN
代表者氏名 Xiaofeng Ma 馬Xiaofeng
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +86 10-6518-1122
設立年月日 38961
市場名 NASDAQ National Market System
ipoyear 2008年
従業員数 551人
adr_tso 10562163
EBITDA EBITDA(百万ドル) 5.53406
終値(lastsale) 1.085
時価総額(marketcap) 11459946.855
時価総額 時価総額(百万ドル) 24.35474
売上高 売上高(百万ドル) 55.80960
企業価値(EV) 企業価値(EV)(百万ドル) -14.97114
当期純利益 当期純利益(百万ドル) 0.13417
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 ATA Inc.(ADR) revenues decreased 100% to RMB296K. Net loss before extraordinary items increased from RMB4.3M to RMB29.7M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Interest income decrease of 54% to RMB453K (income). Basic Earnings per Share excluding Extraordinary Items decreased from -RMB0.09 to -RMB0.66.



   Atai Layoffs 2023: What to Know About the Latest ATAI Job Cuts  2023/03/06 17:27:13 InvestorPlace
The psychedelic drug boom may be taking off, but one company in the space is trimming its workforce. Atai Life Sciences (NASDAQ: ATAI ) just announced it has laid off roughly 30% of its staff. Shares are rising today, but it’s been a very difficult year for this penny stock. After declining more than 62% over the past six months, ATAI stock needs a positive catalyst to turn things around. This is likely part of the reason behind the Atai layoffs, which follow the company’s promise to implement a “company-wide cost optimization” initiative, a measure that hasn’t yet yielded the intended results. Let’s examine the company’s recent announcement and see what investors should be expecting as Atai prepares to hopefully turn a new corner. Atai Layoffs: A Closer Look Part of ATAI stock’s negative performance can be attributed to some poor clinical trial results. The company began the year by announcing disappointing news regarding a Phase 2 trial for PCN-101 (R-ketamine) as a means of addressing treatment-resistant depression.
   Atai stock rises amid restructuring with ~30% job cuts  2023/03/06 12:44:23 Seeking Alpha
Atai Life Sciences (ATAI) has reduced its workforce by ~30% as part of a strategic review and also provided other clinical and corporate updates.Atai noted that the decision to…
   atai Life Sciences to Participate in the Cowen 43rd Annual Health Care Conference  2023/03/01 21:01:00 GlobeNewswire
NEW YORK and BERLIN, March 01, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the Cowen 43rd Annual Health Care Conference.
   The Atai Life Sciences N.V. (ATAI) had a good session last reading, didn’t it?  2023/02/28 16:16:00 US Post News
In Monday’s session, Atai Life Sciences N.V. (NASDAQ:ATAI) marked $1.66 per share, up from $1.62 in the previous session. While Atai Life Sciences N.V. has overperformed by 2.47%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ATAI fell by -69.37%, with highs and lows ranging from […]
   Psychedelic Stock Gainers And Losers From February 21, 2023  2023/02/21 21:30:06 Benzinga
GAINERS: Cybin (AMEX: CYBN ) shares closed up 9.60% at $0.47 LOSERS: ATAI Life Sciences (NASDAQ: ATAI ) shares closed down 8.47% at $1.73 GH Research (NASDAQ: GHRS ) shares closed … Full story available on

 関連キーワード  (事業サポ―トサ―ビス 米国株 ATA ATAI ATA Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)